HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IMCC
IM Cannabis Corp.
There isn't enough reported data to score IMCC yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IMCC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Weak |
IMCC's revenue, profitability, cash flow and balance sheet are all currently weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IMCC PE Valuation
IMCC has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IMCC Forward outlook
There aren't enough analyst estimates for IMCC to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over IMCC in the latest year-over-year earnings comparison.
IMCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2020 | -$629.57 | -$607.83 |
IMCC lost $629.57 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IMCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IMCC on profitability, with a higher operating margin.
IMCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.3M | -40% |
| Q1 2026 | $6.1M | -31% |
| Q4 2025 | $7.9M | -16% |
| Q3 2025 | $9.7M | -0.2% |
| Q2 2025 | $8.9M | -14% |
| Q1 2025 | $8.8M | +3.6% |
| Q4 2024 | $9.4M | +25% |
| Q3 2024 | $9.8M | +12% |
IMCC's revenue has slid since its 2024 peak: $5M last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -28% | -25 points |
| Q1 2026 | -19% | -21 points |
| Q4 2025 | -25% | +123 points |
| Q3 2025 | -30% | -37 points |
| Q2 2025 | -2.8% | -22 points |
| Q1 2025 | 1.3% | +48 points |
| Q4 2024 | -148% | -99 points |
| Q3 2024 | 6.9% | -11 points |
IMCC's operating margin was −28% last quarter, down 25 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IMCC on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$927.5K | -$610.6K |
| Q1 2026 | -$134.3K | -104% |
| Q4 2025 | $1.9M | +$4.8M |
| Q3 2025 | -$2.5M | -231% |
| Q2 2025 | -$317K | -234% |
| Q1 2025 | $3.1M | +$3.6M |
| Q4 2024 | -$3M | -$2.8M |
| Q3 2024 | $1.9M | -50% |
IMCC has burned cash in most quarters: −$2M over the past year, against $2M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IMCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IMCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +35.5K shares |
| 1 year | +166% | +123K shares |
| 3 years | +680% | +172K shares |
IMCC has 197,633 diluted shares, up 166% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IMCC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | 14.0x | High |
| Q4 2023 | 26.3x | High |
IMCC's net debt is about 14 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IMCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 0.6 | Oversold |
IMCC's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IMCC PE vs Healthcare Sector
IMCC has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IMCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.34 | 59% below |
| 20 week MA | $2.68 | 79% below |
| 50 week MA | $15.3 | 96% below |
| 100 week MA | $40.2 | 99% below |
| 200 week MA | $75.3 | 99% below |
IMCC is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over IMCC on returns for 2026, with the stronger performance.
IMCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,556.8 | $15,120.0 | +325% |
| 2021 | $15,120.0 | $6,516.0 | -57% |
| 2022 | $6,516.0 | $189.0 | -97% |
| 2023 | $189.0 | $64.2 | -66% |
| 2024 | $64.2 | $73.2 | +14% |
| 2025 | $73.2 | $42.9 | -41% |
| 2026 YTD | $42.9 | $0.55 | -99% |
IMCC's yearly returns have swung widely, from +325% in 2020 to −97% in 2022. It's down 99% so far in 2026.